Stock Price
137.30
Daily Change
-3.90 -2.76%
Monthly
15.38%
Yearly
-54.49%
Q3 Forecast
130.89



Peers Price Chg Day Year Date
Avita Medical 2.20 0.01 0.46% 35.80% Aug/18
Ansell 35.62 0.14 0.39% 13.40% Aug/19
Cochlear 137.30 -3.90 -2.76% -54.49% Aug/19
CSL 166.48 8.66 5.49% -24.58% Aug/19
Fisher Paykel Healthcare 42.50 0.25 0.59% 12.88% Aug/19
Healius 0.42 -0.03 -5.62% -48.15% Aug/19
Integral Diagnostics 2.24 -0.02 -0.89% -16.73% Aug/19
Mesoblast 2.37 -0.03 -1.25% 2.16% Aug/19
Monash IVF 0.72 0.01 0.70% -12.20% Aug/19
Mayne Pharma 3.23 0 0% -36.29% Aug/19

Indexes Price Day Year Date
ASX200 8985 -16.24 -0.18% 0.76% Aug/19
ASX All Share 9255 -19.02 -0.21% 0.85% Aug/19
AU50 8830 -8.20 -0.09% 1.82% Aug/19

Cochlear traded at 137.30 this Wednesday August 19th, decreasing 3.90 or 2.76 percent since the previous trading session. Looking back, over the last four weeks, Cochlear lost 15.38 percent. Over the last 12 months, its price fell by 54.49 percent. Looking ahead, we forecast Cochlear to be priced at 130.89 by the end of this quarter and at 123.08 in one year, according to Trading Economics global macro models projections and analysts expectations.

Cochlear Limited is an Australian-based company, which provides implantable hearing solutions. The Company designs and offers products and accessories for adults or children. The Company operates through three geographical segments: Americas, EMEA and Asia Pacific. Its products offer various ways to hear, such as automatically adjusting hearing to different environments and streaming sound from a smartphone. It provides various products, including Nucleus sound processors, Smart bimodal hearing solution, Nucleus implants, Nucleus implant reliability, Baha sound processors, Baha implants, Baha Softband, SoundArc. The Company’s accessories include True Wireless devices, Nucleus water-safe accessories, Keeping device in place.